Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon

Journal of Gastroenterology

Volumn 40, Issue 2, 2005, Pages 148-156

  Ikeda, Masafumi ^a,f   Fujiyama, Shigetoshi ^a,b   Tanaka, Motohiko ^a,b   Sata, Michio ^c   Ide, Tatsuya ^c   Yatsuhashi, Hiroshi ^d   Watanabe, Hiroshi ^e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NTT Kyushu General Hospital   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^e FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Sustained response

Indexed keywords

ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE;

ADULT; AGE; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NONBIOLOGICAL MODEL; PATIENT CODING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; CHILD; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET COUNT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 15844367468     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1519-2     Document Type: Article

References (38)

1. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;II:1004-6.
2. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;II:1006-8.
3. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990;355:873-4.
4. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995;21:650-5.
5. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. IHIT Study Group. Ann Intern Med 1999;131:174-81.
6. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321: 1501-6.
7. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
9. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
10. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30.
11. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30:653-9.
12. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-402.
13. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129: 94-9.
14. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-91.
15. Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kumada K, et al. Case report: Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol 1996;11:955-8.
16. Tong MJ, Lai LP, Murakami-Mori K. Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy. West J Med 1997;167:103-5.
17. Miyano S, Togashi H, Shinzawa H, Sugahara K, Matsuo T, Takeda Y, et al. Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol 1999;14:928-30.
18. Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001;16:1131-7.
19. Yamada M, Ichikawa M, Matsubara A, Ishiguro Y, Yokoi S. Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C virus with interferon therapy. Eur J Gastroenterol Hepatol 2000;12:1029-32.
20. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33:1299-302.
21. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004;53:425-30.
22. Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003;9:333-40.
23. Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, et al. Sustained biochemical remission after interferon treatment may be closely related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver Int 2003;23:143-7.
24. Yoneyama K, Yamaguchi M, Kiuchi Y, Morizane T, Shibata M, Mitamura K. Analysis of background factors influencing longterm prognosis of patients with chronic hepatitis C treated with interferon. Intervirology 2002;45:11-9.
25. Komorizono Y, Sako K, Yamasaki N, Hiwaki T, Sakurai K, Shibatou T, et al. Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. Anticancer Res 2002;22:3573-8.
26. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
27. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995;22:457-63.
28. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research group. Gastroenterology 1997;113:558-66.
29. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
30. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347-53.
31. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-4.
32. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
33. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-9.
34. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
35. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: Evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985;5:367-75.
36. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-75.
37. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001;113:590-5.
38. Aster RH. Pooling of platelets in the spleen: Role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1996;45: 645-57.